Ulixacaltamide Receives FDA Breakthrough Designation for Tremor Treatment
Praxis Precision Medicines receives FDA Breakthrough Therapy Designation for ulixacaltamide, a promising new treatment for essential tremor affecting 7 million Americans.
/ 4 items
#PRAX↓
BTIG Boosts Praxis Precision Price Target, Calls It a Top Pick for 2026
BTIG raises its price target on Praxis Precision to $843, citing strong prospects for its essential tremor drug Ulixacaltamide and major growth potential ahead of 2026.
Praxis Precision Medicines Achieves Key Milestones in Neurological Treatments
Praxis Precision Medicines announces FDA alignment for essential tremor drug and positive results for epilepsy treatment, marking major progress in neurological disorder therapies.
Praxis Precision Medicines Stock Surges 170% on Essential Tremor Drug Success
Praxis Precision Medicines stock rallied over 170% after its experimental essential tremor treatment ulixacaltamide exceeded expectations in two Phase 3 trials, defying earlier pessimism.